Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Paola Possanzini"'
Autor:
Michela Palleschi, Roberta Maltoni, Sara Ravaioli, Alessandro Vagheggini, Francesca Mannozzi, Francesca Fanini, Francesca Pirini, Maria Maddalena Tumedei, Eleonora Barzotti, Lorenzo Cecconetto, Samanta Sarti, Silvia Manunta, Paola Possanzini, Anna Fedeli, Annalisa Curcio, Mattia Altini, Ugo De Giorgi, Andrea Rocca, Sara Bravaccini
Publikováno v:
Diagnostics, Vol 10, Iss 8, p 573 (2020)
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expres
Externí odkaz:
https://doaj.org/article/0adf67f7810c4db9830a1083bd264157
Autor:
Alessandro Vagheggini, Roberta Maltoni, Michela Palleschi, Paola Possanzini, Eleonora Barzotti, Anna Fedeli, Sara Bravaccini, Silvia Manunta, Andrea Rocca, Lorenzo Cecconetto, Mattia Altini, Francesca Mannozzi, Annalisa Curcio, Sara Ravaioli, Francesca Pirini, Samanta Sarti, Ugo De Giorgi, Maria Maddalena Tumedei, Francesca Fanini
Publikováno v:
Diagnostics
Diagnostics, Vol 10, Iss 573, p 573 (2020)
Volume 10
Issue 8
Diagnostics, Vol 10, Iss 573, p 573 (2020)
Volume 10
Issue 8
CDK4/6 inhibitors (CDK4/6i) are recommended in patients with estrogen receptor (ER)-positive, HER2-negative advanced breast cancer (ABC). Up to now, no prognostic biomarkers have been identified in this setting. We retrospectively analyzed the expres
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::1c997b77754c122f2021cb44e3596faa
https://pubmed.ncbi.nlm.nih.gov/32784518
https://pubmed.ncbi.nlm.nih.gov/32784518